Search

Displaying results 5281 - 5290 of 5454 in total
  1. Drug

    GC-373

    go.drugbank.com/drugs/DB15797
    Experimental

    It is an inhibitor of M<sup>pro</sup> (otherwise known as 3CL<sup>pro</sup>), a viral encoded protease that cleaves and activates functional proteins involved in viral replication and transcription[A219036

  2. Drug

    MYR-101

    go.drugbank.com/drugs/DB17075
    Investigational

    It is caused by a mutation in the aspartoacylase gene (_ASPA_), which leads to a deficiency of the aspartoacylase enzyme (ASPA).

  3. Drug

    Telaprevir

    go.drugbank.com/drugs/DB05521
    ApprovedWithdrawn

    Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance.

    Products: INCIVO® TABLETAS RECUBIERTAS 375 MG
  4. Drug

    Chlorotoxin I-131

    go.drugbank.com/drugs/DB05462
    Investigational

    It is a synthetic version of a neurotoxin isolated from the venom of the Giant Yellow Israeli scorpion Leiurus quinquestriatus.

  5. Drug

    ZYCOV-D

    go.drugbank.com/drugs/DB15892
    Experimental

    Once the plasmid DNA is introduced into host cells and the viral protein is translated, it elicits a strong immune response, stimulating the humoral and cellular components of the immune system[L16503]

  6. Drug

    BBV152

    go.drugbank.com/drugs/DB15847
    Investigational

    Animal studies in mice, rats, and rabbits reported BBV152 immunogenicity at two separate antigen concentrations with both types of adjuvants.

  7. Drug

    TRC093

    go.drugbank.com/drugs/DB06356
    Investigational

    TRC093 is a recombinant humanized IgG1k monoclonal antibody.

  8. Drug

    Brentuximab

    go.drugbank.com/drugs/DB05471
    Investigational

    It is available commercially as the monoclonal antibody portion of the antibody-drug conjugate [brentuximab vedotin]. … SGN-30 received orphan drug designation from the FDA in July 2003 for Hodgkin lymphoma and in February 2004 for T-cell lymphomas.

  9. Drug

    Stem-cell derived exosome vesicle products

    go.drugbank.com/drugs/DB15743
    Experimental

    While many contain a conserved set of proteins, they also carry unique tissue type-specific proteins.

  10. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively.